Question explored with the scientific record
Was ozempic tested properly
The short version: Ozempic was tested for surrogate endpoints like HbA1c and weight loss, not for whether it makes you live longer or healthier overall.
The SUSTAIN and PIONEER trials were funded by Novo Nordisk, the manufacturer [1, 13]. They compared semaglutide to placebo or other drugs in people with type 2 diabetes, showing it lowers blood sugar and body weight [1, 3, 11]. The largest cardiovascular safety trial, SUSTAIN 6, enrolled 3,297 high-risk patients and found fewer heart attacks and strokes (hazard ratio 0.74) but also more diabetic retinopathy events (3.0% vs 1.8%) [14]. That trial lasted only two years, and the retinopathy signal was never fully explained [14].
The weight-loss trials (STEP program) were also manufacturer-funded and lasted 68 weeks at most [6, 15]. They show people lose about 15% of body weight on the 2.4 mg dose, but gastrointestinal side effects are very common: nausea in 42% of patients in one NASH trial [2], and about 7% of people stop the drug because of side effects [11]. No trial has followed people for more than a few years, so long-term effects on cancer, pancreatitis, or thyroid disease are unknown. The evidence says the drug changes lab values and body weight in the short term. It does not say what happens to you five or ten years later.
My call: Ozempic was tested for short-term metabolic effects in manufacturer-funded trials, but the evidence for long-term safety and net health benefit is thin. Confidence: moderate for short-term efficacy, low for long-term safety.
Sources examined 16
-
Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial
The SUSTAIN 5 trial demonstrated that semaglutide, when added to basal insulin, significantly improves glycemic control and reduces body weight in patients with type 2 diabetes compared to placebo.
DOI: 10.1210/jc.2018-00070 -
The Glucagon‐Like Peptide‐1 Receptor Agonist, Semaglutide, for the Treatment of Nonalcoholic Steatohepatitis
In a randomized, placebo-controlled trial, subcutaneous semaglutide at 0.4 mg weekly induced histologic resolution of nonalcoholic steatohepatitis (NASH) without worsening fibrosis in a large portion of patients with biopsy‑proven NASH (F2–3), accompanied by dose‑dependent weigh…
DOI: 10.1002/hep.31886 -
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
This phase 3a trial demonstrated that once-weekly semaglutide 1.0 mg is superior to exenatide extended release 2.0 mg in improving glycemic control and reducing body weight in adults with type 2 diabetes inadequately controlled on oral antidiabetic drugs.
DOI: 10.2337/dc17-0417 -
GLP-1 receptor agonists as an adjunct to bariatric surgery for weight loss and metabolic outcome improvement: a systematic review and meta-analysis
This study systematically reviews and meta-analyzes GLP-1 receptor agonists used before or after bariatric surgery to improve weight loss and metabolic outcomes in adults with insufficient weight loss or weight regain, finding that liraglutide, semaglutide, and especially tirzep…
DOI: 10.1007/s00423-025-03831-4 -
Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial
Protocol for a randomized, single-blind, placebo-controlled trial to test whether semaglutide modulates tongue transcriptomics, sweet-taste sensitivity, and neural responses to food cues in obese women with PCOS.
DOI: 10.1186/s13063-021-05442-y -
Long Term Management of Obesity with Once Weekly Semaglutide Efficacy and Safety in Clinical Trials
Weekly semaglutide 2.4 mg yields substantial, durable weight loss in adults with overweight/obesity across STEP trials, with gastrointestinal adverse events as the main safety signal.
DOI: 10.52768/2995-5874/1029 -
Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
A systematic review and meta-analysis of 11 randomized controlled trials including 935–936 adults with NAFLD/NASH shows GLP-1 receptor agonists (liraglutide, exenatide, dulaglutide, semaglutide) reduce liver fat content by MRI-based methods and improve liver enzymes, with two sm…
DOI: 10.3390/metabo11020073 -
Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial
A double-blind, phase 1 randomized controlled trial in healthy Chinese adults showing dose-proportional pharmacokinetics and acceptable safety/tolerability for once-weekly subcutaneous semaglutide at 0.5 mg and 1.0 mg, with no new safety signals and support for no dose adjustmen…
DOI: 10.1007/s12325-020-01548-y -
Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with OUD: a randomized, double-blind, placebo-controlled clinical trial protocol
A phase II randomized, double-blind, placebo-controlled trial protocol to evaluate whether once-weekly semaglutide (GLP-1 receptor agonist) increases abstinence from illicit/nonprescribed opioids and reduces craving in adults with opioid use disorder who remain positive for nonp…
DOI: 10.1186/s13722-025-00618-2 -
Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
The PIONEER 6 trial is a multinational, randomized, placebo-controlled study designed to assess the cardiovascular safety of oral semaglutide in patients with type 2 diabetes at high risk for cardiovascular events, enrolling 3,183 patients with a mean age of 66.1 years and a mea…
DOI: 10.1111/dom.13553 -
Greater Combined Reductions in Hba1C ≥1.0% and Weight ≥5.0% with Semaglutide Versus Comparators in type 2 Diabetes
Post hoc analysis of the SUSTAIN 1-5 and 7 trials shows that once-weekly subcutaneous semaglutide achieves greater proportions of patients with both a ≥1.0% HbA1c reduction and ≥5.0% weight loss than comparators, with a dose-dependent effect and acceptable safety across diverse …
DOI: 10.4158/ep-2018-0444 -
Effects of GLP-1RAs on cardiovascular outcomes in patients with type 2 diabetes mellitus: review of real-world data on target populations from diabetes registry in Russian Federation
GLP-1 receptor agonists reduce major adverse cardiovascular events and renal outcomes in type 2 diabetes across major randomized trials, while Russian registry data reveal a large eligible population with very low real-world uptake.
DOI: 10.14341/dm12803 -
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials
A comprehensive synthesis of the SUSTAIN 1-7 phase 3 trials showing that once-weekly subcutaneous semaglutide provides superior glycemic control and weight loss across a broad type 2 diabetes population, with demonstrated cardiovascular safety in the high‑risk SUSTAIN 6 trial.
DOI: 10.1016/j.diabet.2018.12.001 -
Safety of injectable semaglutide for type 2 diabetes
A narrative safety review of injectable semaglutide for type 2 diabetes, synthesizing safety data from the SUSTAIN programme and related analyses, highlighting overall good safety with gastrointestinal effects, potential renoprotection, a signal for diabetic retinopathy risk lik…
DOI: 10.1080/14740338.2020.1772230 -
Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management
A narrative review synthesizing semaglutide’s weight-loss evidence across the SUSTAIN, PIONEER, and STEP randomized trials (subcutaneous and oral forms) in adults with overweight/obesity, with or without type 2 diabetes, highlighting efficacy, safety, and clinical implications f…
DOI: 10.1136/jim-2021-001952 -
Origins of the Crisis in Insulin Affordability and Practical Advice for Clinicians on Using Human Insulin
High insulin prices in the US are driven by an opaque reimbursement system, alleged price-fixing, and weak generic competition; prescribing human insulin can be a cost-saving, clinically acceptable option for many patients with type 2 diabetes.
DOI: 10.1007/s11892-020-1286-3